Century Therapeutics(US:IPSC)2025-11-13 12:52Financial Performance - Century Therapeutics reported a net loss of $34.4 million for Q3 2025, compared to a net loss of $31.2 million in Q3 2024, reflecting a year-over-year increase in losses of approximately 7.3%[7] - Research and Development (R&D) expenses decreased to $22.5 million in Q3 2025 from $27.2 million in Q3 2024, a reduction of about 17.3%[6] - General and Administrative (G&A) expenses were $6.8 million for Q3 2025, down from $8.4 million in Q3 2024, representing a decrease of approximately 19%[6] - Total assets decreased to $244.7 million as of September 30, 2025, from $353.2 million as of December 31, 2024, a decline of approximately 30.7%[12] Cash Position - Cash, cash equivalents, and marketable securities totaled $132.7 million as of September 30, 2025, down from $220.1 million as of December 31, 2024, indicating a decrease of about 39.7%[6] - The company estimates its cash runway will support operations into the fourth quarter of 2027[4] Clinical Development - The company anticipates initiating IND-enabling studies for its lead beta islet program, CNTY-813, by the end of 2025, with an IND submission planned for as early as 2026[4] - CNTY-308 is progressing through IND-enabling studies, with clinical study initiation expected in 2026[4] - Century Therapeutics has generated compelling preclinical data for its iPSC-derived beta islet program, indicating potential for rapid and sustained glucose control without chronic immune suppression[3] - Initial clinical data from the CNTY-101 trial in CARAMEL is expected to be presented on December 5, 2025[6]